Traws Pharma Inc.
TRAW
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.26M
Close$
$0.73
112.3% upside
Current Fair Value
112.3% upsideUndervalued by 112.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.26 Million |
|---|---|
| Enterprise Value | $2.13 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.83 |
| Beta | 1.53 |
| Outstanding Shares | 10,640,625 |
Return
| Return on Equity | 74224.25% |
|---|---|
| Return on Assets | -48333.13% |
| Return on Invested Capital | 80435.79% |
Valuation & Multiples
| P/E Ratio | -0.69 |
|---|---|
| PEG | 2.16 |
| Price to Sales | - |
| Price to Book Ratio | -0.34 |
| Enterprise Value to Revenue | 0.39 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$2.71 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 57.86%▲ 23.84% |
|---|---|
| Total Invested | $5.19M▼ 21.64% |
| Investors Holding | 34▲ 7.00% |
ESG Score
No data
About Traws Pharma Inc.
31 employees
CEO: Steven Fruchtman onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has cre...